X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.centerforbiosimilars.com/view/henlius-pertuzumab-biosimilar-shows-similar-pk-profile-to-reference-product-in-first-human-study
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/roche-launches-antibody-drug-for-breast-cancer-in-india/articleshow/91526195.cms
https://seekingalpha.com/news/3766692-bristol-myers-squibb-posts-encouraging-data-from-late-stage-opdivo-lung-cancer-trial
http://www.pharmatimes.com/news/uk_cancer_centre_to_offer_breast_cancer_treatment_at_home_1368444
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020
https://www.fiercepharma.com/pharma/roche-wards-off-herceptin-copycats-new-easy-to-use-perjeta-combo-product
https://www.prnewswire.com/news-releases/fda-approves-breast-cancer-treatment-that-can-be-administered-at-home-by-health-care-professional-301085174.html
https://www.prnewswire.com/news-releases/halozyme-announces-fda-has-accepted-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-using-enhanze-technology-301010295.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409
http://www.pmlive.com/pharma_news/ema_backs_adjuvant_use_of_roches_breast_cancer_adc_kadcyla_1320584
https://www.cnbc.com/2019/11/28/reuters-america-drugmakers-slash-prices-in-china-to-get-on-reimbursement-list.html
https://www.fiercepharma.com/manufacturing/u-k-s-labour-party-wants-government-to-build-its-own-manufacturing-to-lower-drug
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
http://www.pmlive.com/pharma_news/roche_preps_filings_for_herceptinperjeta_combination_1301521
https://www.fiercepharma.com/pharma/genentech-to-settle-biosimilar-trade-secret-theft-suit-taiwan-s-jhl
https://www.thepharmaletter.com/in-brief/brief-chugai-seeks-new-kadcyla-indication-in-japan
https://www.reuters.com/article/us-astrazeneca-breast-cancer-study/astrazeneca-daiichi-sankyo-breast-cancer-drug-shows-promise-idUSKCN1SE0LJ?feedType=RSS&feedName=healthNews
https://www.bloombergquint.com/business/roche-s-new-cancer-ms-drugs-pay-off-with-a-forecast-boost
https://www.fiercepharma.com/pharma/roche-s-stellar-hemlibra-ocrevus-results-q1-prompt-sunnier-2019-outlook
http://www.pharmatimes.com/news/smc_oks_four_meds_for_nhs_use,_including_roches_perjeta_1275014
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409
https://www.prnewswire.com/news-releases/neuclone-announces-its-sixth-biosimilar-candidate-perjetar-pertuzumab-for-use-in-combination-therapy-with-herceptinr-trastuzumab-300767208.html
http://www.pharmatimes.com/news/smc_accepts_four_medicines_for_nhs_use_1272386
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409
http://www.pharmatimes.com/news/nice_sticks_with_no_for_use_of_perjeta_after_breast_cancer_surgery_1249275
https://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/
https://www.fiercepharma.com/pharma/roche-ups-2018-guidance-again-as-ocrevus-steams-pass-blockbuster-threshold
https://www.reuters.com/article/us-roche-results/upbeat-roche-bests-rival-novartis-as-new-drugs-fuel-growth-idUSKBN1KG0EP
https://www.fiercepharma.com/pharma/patients-wait-for-years-as-vertex-u-k-officials-argue-over-orkambi-price
http://www.pharmatimes.com/news/nice_rejects_adjuvant_use_of_perjeta_post-surgery_1240029
https://www.fiercepharma.com/pharma/nice-dogs-roche-s-perjeta-again-time-postsurgery-breast-cancer-patients
https://www.reuters.com/article/us-roche-breast-cancer-perjeta/roches-perjeta-wins-approval-in-europe-for-expanded-use-idUSKCN1IX5CI
Market Place
Share 
